Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential

Inclusion Criteria cohort (NSCLC-IC): * Age \>18 years; * Histological diagnosis of NSCLC * metastatic disease * Availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (surgical or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy); * ECOG PS 0-2; * Adequate hematological, hepatic and renal function; * Measurable disease according to RECIST criteria * Availability of follow-up data for at least 6 months and/or until death/progression Exclusion Criteria cohort (NSCLC-IC): * Previous systemic therapy for metastatic disease; * Comorbidities not controlled with adequate medical therapy. Inclusion Criteria NSCLC-VC cohort: * Age \>18 years; * Histological diagnosis of NSCLC * metastatic disease * Availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (during surgery and/or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy); * ECOG PS 0-2; * Adequate hematological, hepatic and renal function; * Measurable disease according to RECIST criteria; * Written informed consent (participation in the study and data processing) Exclusion Criteria NSCLC-VC cohort: * Previous systemic treatment for metastatic disease; * Comorbidities not controlled with adequate medical therapy;